NL-OMON41716
Completed
Not Applicable
therapeutic drug monitoring: towards tailored dosing of adalimumab in rheumatoid arthritis - therapeutic drug monitoring of adalimumab in rheumatoid arthritis
Reade, centrum voor Revalidatie en Reumatologie0 sites55 target enrollmentTBD
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- rheumatoide arthritis
- Sponsor
- Reade, centrum voor Revalidatie en Reumatologie
- Enrollment
- 55
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •RA according to the ACR 1987 criteria
- •Adalimumab treatment for at least 28 weeks
- •Trough adalimumab level \> 12 mg/L
- •Treating rheumatologist is convinced of the benefit of adalimumab continuation
- •Written informed consent
Exclusion Criteria
- •Scheduled surgery in the next 6 months or other pre planned reasons for treatment discontinuation.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
Therapeutic drug monitoring: Toward tailored dosing of adalimumab in rheumatoid arthritis.rheumatoid arthritisadalimumabtherapeutic drug monitoringNL-OMON29559ReumafondsReade, centrum voor revalidatie en reumatologie102
Completed
Phase 3
Therapeutic drug monitoring-based dose optimisation of piperacillin in patients with severe sepsis or septic shock to investigate effects on organ functions and survival: a prospective, multicenter, randomized controlled trialR65.1R57.2Systemic Inflammatory Response Syndrome of infectious origin with organ failureSeptic shockDRKS00011159Friedrich-Schiller-Universität Jena254
Completed
Not Applicable
Therapeutic Drug Monitoring to Individualize the Dosing of pazopanib: a Randomized Pharmacokinetic Feasibility Studyadvanced tumors for which no treatment options are availablerenal cell cancer10038588NL-OMON37356eids Universitair Medisch Centrum13
Active, not recruiting
Phase 1
Measurement of the blood concentration of the antibiotic piperacillin and individual drug dosage in patients with febrile neutropenia after chemotherapyPatients with febrile neutropenia after myelo-suppressive chemotherapy treated with piperacillin/tazobactamTherapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]EUCTR2016-002388-33-DEFriedrich-Schiller-University Jena208
Withdrawn
Not Applicable
se of therapeutic drug monitoring (TDM) to optimise oral/enteral hydroxychloroquine dosing in critically ill patients with COVID-19COVID-19Infection - Other infectious diseasesRespiratory - Other respiratory disorders / diseasesACTRN12620000447954Royal Brisbane & Women's Hospital150